Nexstim Abp i teknologi licens förhandlingar med ett ledande akademiskt institut i Kalifornien
October 02, 2019 02:00 ET
|
Nexstim Oyj
Pressmeddelande, Helsingfors, 2 oktober 2019 kl 9.00 (EEST) Nexstim Abp i teknologi licens förhandlingar med ett ledande akademiskt institut i Kalifornien Nexstim Abp (NXTMH:HEX, NXTMS:STO)...
Square Medical Group is Now Offering Mental Health Technology for Major Depressive Disorder (MDD) in Offices Across Massachusetts
September 12, 2019 09:00 ET
|
Square Medical Group
DANVERS, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Square Medical Group, an integrated, multidisciplinary private group practice providing a full-range of outpatient mental health and chemical...
NuMe TMS Clinics Now Offer FDA-Cleared Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD) in Houston
August 06, 2019 09:00 ET
|
NuMe TMS Clinics
HOUSTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- NuMe TMS Clinics, a group of mental health clinics dedicated to serving its communities with safe and effective mental health treatments, today announced...
Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates
August 05, 2019 07:30 ET
|
Minerva Neurosciences, Inc
During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in major depressive...
Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
June 24, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
First patient enrolled in placebo-controlled GEMINI study Topline results anticipated in 2H 2019 NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting
May 21, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
May 13, 2019 08:15 ET
|
Minerva Neurosciences, Inc
Potential first-in-class, oral specific orexin-2 inhibitor demonstrates statistically significant improvement in MADRS scores at 6 weeks compared to placebo Well tolerated, with adverse events similar...
Axsome Therapeutics Announces Expedited Development and Pivotal Status for AXS-05 in the Treatment of Major Depressive Disorder based on FDA Breakthrough Therapy Meeting
May 06, 2019 06:30 ET
|
Axsome Therapeutics, Inc.
Previously completed active-controlled ASCEND trial in MDD now considered as pivotal; sufficient with ongoing STRIDE-1 Phase 3 trial for NDA in MDD Target randomization for STRIDE-1 Phase 3 trial...
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder
March 27, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Designation offers potential for expedited development and review NEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company...
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder
January 07, 2019 06:00 ET
|
Axsome Therapeutics, Inc.
Demonstrated statistically significant improvement in MADRS scores compared to active comparator (p<0.001 on primary endpoint) Rapid improvement in depressive symptoms demonstrating statistically...